MAIA Biotechnology, Inc.

MAIA NYSE CIK: 0001878313

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 444 WEST LAKE STREET, SUITE 1700, CHICAGO, IL, 60606
Mailing Address 444 WEST LAKE STREET, SUITE 1700, CHICAGO, IL, 60606
Phone 312-416-8592
Fiscal Year End 1231
EIN 000000000

Financial Overview

FY2025

-$22.40M
Net Income
$10.16M
Total Assets
-
Cash & Equivalents
$-0.70
EPS

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events March 31, 2026 View on SEC
8-K Current report of material events March 27, 2026 View on SEC
10-K Annual financial report March 23, 2026 View on SEC
424B5 Prospectus supplement March 4, 2026 View on SEC
8-K Current report of material events March 4, 2026 View on SEC
424B5 Prospectus supplement March 2, 2026 View on SEC
8-K Current report of material events February 24, 2026 View on SEC
8-K Current report of material events January 20, 2026 View on SEC
8-K Current report of material events January 13, 2026 View on SEC
4 Insider stock transaction report January 12, 2026 View on SEC

Annual Reports

10-K March 23, 2026
  • MAIA successfully raised $24.4 million in 2024 through diverse funding strategies to advance its drug pipeline, especially THIO.
  • The company maintains financial flexibility with an At-The-Market (ATM) program, with $21.3 million remaining available for future capital raises.
View Analysis

Insider Trading

STRONG BUY 5 insiders 20 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.